Home / Market News / $JNJ
benzinga Corporate Catalyst Impact 92/100 ● neutral

Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call

Oct 13, 2026, 1:47 PM UTC · Primary ticker $JNJ

Johnson & Johnson reported robust Q3 2026 results, exceeding $25 billion in revenue and raising its full-year operational sales growth guidance to 6.7%-7.1%. This strong performance, driven by its Innovative Medicine division, positions the company to surpass $100 billion in annual revenue for the first time, indicating significant positive momentum for its stock.

Johnson & Johnson (JNJ) announced strong third-quarter 2026 earnings, with operational sales growth of 6% and revenues exceeding $25 billion. This performance led the company to raise its full-year 2026 guidance, now expecting operational sales growth of 6.7% to 7.1%. This is a significant positive catalyst for JNJ, as it indicates robust business health, particularly in its Innovative Medicine division (oncology and immunology), and a clear path to exceeding $100 billion in annual revenue. The raised guidance and strong pipeline, including strategic acquisitions and collaborations, suggest sustained growth and confidence from management, which could lead to increased investor confidence and a positive short-term and long-term outlook for the stock.

$JNJ positive Strong Q3 2026 results and raised full-year guidance
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.